TORONTO, March 04, 2020 (GLOBE NEWSWIRE) — Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is pleased to announce its engagement with Emergent BioSolutions (NYSE: EBS), a global life sciences company whose mission is to protect and enhance life by providing specialty products and contract development and manufacturing services that address public health threats.
Andrew Schachter, Founder & CEO of Axiom, shared, “Axiom is passionate about giving sponsors solutions that harness the power of their data to drive clinical research. We deliver technology and services to innovative life sciences organizations to provide them with the information that they need – in real-time – so that they are empowered with the robust and timely insights which are required for compliance, effective trial conduct, and successful drug development. We are very pleased to build this relationship with Emergent and potentially be a long-term partner in meeting their evolving needs as they develop drugs that are critical to patient well-being and position them at the leading edge of infectious disease treatments.”
Paul-André de Lame, VP, Clinical Development at Emergent stated, “We are delighted to have found a fully integrated clinical suite that will allow us to scale up seamlessly while optimizing our processes to capitalize on the unmatched potential offered by Axiom’s Fusion platform.”
Meredith Frank-Molnia, Senior Director Clinical Management at Axiom, expressed, “We are integral partners to our sponsors, driving clinical development success through the unique combination of thoughtful planning, best-in-class Fusion eClinical technology, and our Axiom team members who are passionately dedicated to their trials.”
“Emergent has a distinctive position in the life sciences space with its focus on infectious disease and endemic illness. Their choice of Axiom’s unified technology platform to deploy end-to-end solutions quickly is a major source of pride for us and validates our mission,” further contributed Kaitlyn Townsley, Associate Director of Product Innovation at Axiom.
“We fully appreciate the importance and the trust that our clients place in us. Emergent is engaging us to empower their studies, which we know may affect generations to come. We look forward to a long-term strategic relationship with such an innovative and leading-edge client; one poised to have such significant impact to the health and well-being of so many,” concluded Andrew Schachter.